Artiva Biotherapeutics, Inc. ARTV 深 沪
已收盘 09-19 16:00:00 美东时间
2.88
+0.500
+21.01%
华盛通- 最 高2.98
- 今 开2.39
- 成交量 47.87万股
- 最 低 2.37
- 昨 收 2.38
- 总市值 7034.63万
- 52周最高 17.31
- 市盈率 静 --
- 换手率 1.96%
- 52周最低 1.47
- 委 比 50.38%
- 总股本 2442.58万
- 历史最高 17.31
- 量 比 5.55
- 振 幅 25.63%
- 历史最低 1.47
- 每 手 1
- 风险率 1.59%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Artiva Biotherapeutics Reports Progress in Clinical Trials
Artiva Biotherapeutics, Inc. ( ($ARTV) ) has released its Q2 earnings. Here is ...
08-29 12:10
Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights
Artiva Biotherapeutics announced progress in its clinical trials for AlloNK® in autoimmune diseases, including treating the first patient in a global basket trial for refractory rheumatoid arthritis, Sjögren’s disease, and systemic sclerosis. Over a dozen patients have been treated across multiple sites. Initial safety and efficacy data are expected by year-end 2025, with clinical response data in the lead indication anticipated in 1H2026. The co...
08-06 20:05
美股大行评级 | GitLab遭多家大行下调目标价！Stifel首予优步"买入"评级，目标价110美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139839943846023169.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Loop Capital：维持Dave & Buster's Enter(PLAY)"买入"评级，目标价从35美元升至46美元</p> <p>• Stifel：维持嘉年华(CCL)"买入"评级，目标价从31美元升至
06-12 09:46
HC Wainwright & Co. Assumes Artiva Biotherapeutics at Buy, Announces Price Target of $12
HC Wainwright & Co. analyst Emily Bodnar assumes Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy rating and announces Price Target of $12.
06-11 19:03
Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference
Artiva Biotherapeutics announced its participation in the Jefferies Global Healthcare Conference on June 4, 2025, where management will engage in a fireside chat and investor meetings. The company focuses on developing cell therapies for autoimmune diseases and cancers, with its lead program, AlloNK®, currently in clinical trials. Artiva, headquartered in San Diego, was established in 2019 as a spin-out from GC Cell in South Korea. For more detai...
05-28 20:05
美股大行评级 | 潜在涨幅1281.22%！Cabaletta Bio获Guggenheim升目标价至25美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130057143861719040.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Cabaletta Bio(CABA)"买入"评级，目标价从23美元升至25美元</p> <p>• 瑞穗：维持Tectonic Therapeutic(TECX)"跑赢大市"评级，目标价从51美元
05-16 08:43
Artiva Biotherapeutics Announces Longer-Term Phase 1/2 Data Demonstrating Prolonged Durability For AlloNK In Combination With Rituximab In Patients With B-cell-Non-Hodgkin Lymphoma At The ASGCT 28th Annual Meeting
64% (9/14) complete response rate with AlloNK + rituximab in heavily pretreated patients that were naïve to prior CAR-T cell therapy, in line with approved auto-CAR-T therapies in aggressive B-NHLMedian duration of
05-14 04:30
Artiva Biotherapeutics Reports Q1 2025 Progress
Artiva Biotherapeutics, Inc. ( ($ARTV) ) has released its Q1 earnings. Here is ...
05-11 11:51
Artiva Biotherapeutics GAAP EPS of -$0.83
Artiva Biotherapeutics press release (NASDAQ:ARTV): Q1 GAAP EPS of -$0.83. As of March 31, 2025, Artiva had cash, cash equivalents, and investments of $166.0 million which is expected to fund operatio...
05-08 22:22
